Imbruvica (ibrutinib) — Medica
Marginal Zone Lymphoma (including gastric MALT, non-gastric MALT, nodal marginal zone lymphoma, splenic marginal zone lymphoma)
Initial criteria
- Patient is age ≥ 18 years
- Patient is continuing therapy with Imbruvica
- Patient has tried at least one systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, lenalidomide)
Reauthorization criteria
- Patient continues to meet initial criteria
Approval duration
1 year